Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 900271 24 0?
Displaying drugs 1 - 25 of 1583 in total
Streptococcus pneumoniae type 23f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 23f of Streptococcus pneumoniae. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Approved
Investigational
Matched Mixtures name: … Pneumovax 23 ... Pneumovax 23 ... Pneumovax 23
Matched Products: … Pneumovax 23 ... PNEUMOVAX 23 (PREFILLED SYRINGE) …
Aluminum zirconium tetrachlorohydrex gly is a common active ingredient in personal care products as an antiperspirant agent. Its main mechanism of action is through blocking the pores via formation of polymer complex and preventing sweat from leaving the body.
Approved
Matched Products: … Women's - Stk 23% ... Zel Stk A/p Ladies Scented 23% ... Big V Ladies Anti Stk 23% Unscent …
Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.[L46237,L46257] Mirikizumab is approved in Japan and received a positive opinion from the EMA's Committee for Medicinal...
Approved
Investigational
Matched Description: … It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways …
Matched Categories: … Interleukin-23 Antagonist …
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows ... The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every …
Matched Categories: … Interleukin-23 Antagonist ... Interleukin-23 Subunit p19 …
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23 ... IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the …
Matched Categories: … Interleukin-23 Antagonist ... Interleukin-23 Subunit p19 …
Streptococcus pneumoniae type 9n capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 9n of Streptococcus pneumoniae. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Approved
Investigational
Matched Mixtures name: … Pneumovax 23 ... Pneumovax 23 ... Pneumovax 23
Streptococcus pneumoniae type 15b capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 15b of Streptococcus pneumoniae. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Approved
Investigational
Matched Mixtures name: … Pneumovax 23 ... Pneumovax 23 ... Pneumovax 23
Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions...
Approved
Investigational
Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage.[A190975,A190978] PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary...
Approved
Vet approved
Matched Salts name: … Polyoxyethylene 23 lauryl ether …
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a...
Approved
Investigational
Matched Mixtures name: … ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 23 ADET 180 MG ... ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 23 ADET 180 MG …
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Approved
Experimental
Matched Mixtures name: … Ageless Foundation 23
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Matched Description: … Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23
Matched Categories: … Fibroblast Growth Factor-23 Blocking Antibodies …
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Approved
Investigational
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from lactose. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. sucrose). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides...
Approved
Investigational
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Approved
Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Approved
Vet approved
Matched Salts cas: … 136-47-0
Matched Mixtures name: … Lidocaine 23% / Tetracaine 7% ... Lidocaine 23% / Tetracaine 7% …
Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population....
Approved
Investigational
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the...
Approved
Investigational
Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis.[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first...
Approved
Matched Salts cas: … 79307-93-0
Matched Mixtures name: … DYMİSTA 137 MCG + 50 MCG BURUN SPREYİ, SÜSPANSİYON, 23 G …
Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m . It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity .
Approved
Matched Mixtures name: … Dpc Pink Aura Cushion No.23
In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized. Also known as, BAY94-9027,...
Approved
Investigational
Matched Description: … [A38907] Also known as, BAY94-9027, Damoctocog alfa pegol is a longer-acting Factor VIII therapy formulated …
Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Approved
Investigational
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Displaying drugs 1 - 25 of 1583 in total